HER2

News

Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.

News

Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.

News

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.